Source: BRL Medicine

On January 8, 2026, BRL Medicine, which focuses on gene and cell therapy, officially announced,Dr. Xiang Yu officially joined BRL Medicine on January 1, 2026, as the Chief Executive Officer (CEO).Dr. Xiang Yu willFully responsible for the company's strategic planning, resource allocation, and overall operational management., leading BRL Medicine to achieve high-quality development during the critical phase of a comprehensive upgrade in "globalization, commercialization, and industrialization," and accelerating the clinical translation and market entry of multiple cutting-edge gene and cell therapy products worldwide.

Dr. Xiang Yu has nearly two decades of management experience deeply rooted in the pharmaceuticals industry, having held key leadership positions such as President of multinational pharmaceutical companies in China and CEO of innovative drug enterprises. He possesses comprehensive capabilities in strategic planning, business growth, and commercial implementation, with notable achievements in innovative pipeline layout, NDA approvals, new product launches, NRDL negotiations and multi-channel market access, as well as digital ecosystem development. He excels at driving corporate transformation and sustainable development with a global perspective.。

Dr. Xiang Yu holds a Ph.D. from Yale University and a bachelor's degree from Peking University. His career began atMcKinsey & Company`, with a background in strategic consulting in the healthcare sector.`

Thereafter inNovartis PharmaceuticalsDuring this period, he served as the Global Headquarters Strategy Director and held leadership roles in multiple divisions in the China region, achieving significant accomplishments in building business teams, launching new products, and driving scaled growth.

He also once served asAbbottDiabetesGeneral Manager of Greater China and Emerging Asia, successfully driving significant growth and profitability in China's business.

Later, he served as the head of an innovative rare disease pharmaceutical company.Langyu GroupCEO，Comprehensively lead the company's strategy, R&D, and commercialization, achieving key milestones in the launch of new rare disease drugs and their inclusion in medical insurance.

Before joining BRL Medicine, Dr. Yu Xiang served as a senior executive at Santen Pharmaceutical (China) Co., Ltd.Santen PharmaceuticalPresident of Greater China, fully responsible for the overall business operations management of Santen's largest overseas market, and promoting the transformation of the company's business growth model.Successfully reached multiple important BD collaborations, optimizing the innovative pipeline layout.

Dr. Xiang Yu's systematic experience, strategic vision, and leadership are highly aligned with BRL Medicine's current strategy to accelerate the R&D and commercialization process.